Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
AvantiCell Science was a Scottish biotechnology company specializing in the development of advanced human cell-based analysis tools, including ethically sourced primary human cells and next-generation organoids. Their proprietary technologies enabled more physiologically relevant alternatives to animal testing for drug discovery, materials testing, and biomedical research. The company developed both first-generation market-ready products for two-dimensional analysis as well as second-generation three-dimensional immune cell/organoid models using bioprinting. These innovations aimed to improve the predictive value of preclinical safety/efficacy tests—especially for liver toxicity—and accelerate safer drug development. The company was dissolved on July 26, 2023.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on AvantiCell Science.